优化肺癌筛查试验(WF-20817CD):多中心随机有效性实施试验以促进肺癌筛查者的戒烟
OaSiS研究是一项在社区放射科开展的有效性-实施混合II型整群随机试验,将26家机构随机分为干预组或常规组,纳入55-77岁正在吸烟的肺癌筛查者。结果显示两组在14天、3个月和6个月的7天烟草使用 abstinence 上均无显著差异,但随时间推移戒烟率显著增加。
要点
- 干预措施未显著提高肺癌筛查者的戒烟率。
- 社区放射科实施戒烟干预的效果需进一步优化。
核心结论
- OaSiS干预未能在肺癌筛查者中显著改善戒烟结局。
- 所有参与者随时间推移烟草使用显著减少,但组间无差异。
研究设计与样本
- 有效性-实施混合II型整群随机试验,26家社区放射科随机分为干预组或常规组。
- 纳入1094名55-77岁正在吸烟的肺癌筛查者,956人完成6个月随访(保留率86%)。
主要发现
- 自报戒烟率在机构间差异大(0%-27%)。
临床怎么用
- 在肺癌筛查环境中,常规戒烟干预策略可能需要进一步优化以提高效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One-half of all people who undergo lung cancer screening (LCS) currently use tobacco. However, few published studies have explored how to implement effective tobacco use treatment optimally during the LCS encounter. RESEARCH QUESTION: Was the Optimizing Lung Screening intervention (OaSiS) effective at reducing tobacco use among patients undergoing LCS in community-based radiology facilities? STUDY DESIGN AND METHODS: The OaSiS study (National Cancer Institute [NCI] Protocol No.: WF-20817CD) is an effectiveness-implementation hybrid type II cluster randomized trial of radiology facilities conducted in partnership with the Wake Forest National Cancer Institute Community Oncology Research Program research base. We randomly assigned 26 radiology facilities in 20 states to the intervention or usual care group. Staff at intervention facilities implemented a variety of strategies targeting the clinic and care team. Eligible patient participants were aged 55 to 77 years undergoing LCS and currently using tobacco. Of 1,094 who completed a baseline survey (523 intervention group, 471 control group) immediately before the LCS appointment, 956 completed the 6-month follow-up (86% retention rate). Fifty-four percent of those who reported not using tobacco at 6 months completed biochemical verification via mailed cotinine assay. Generalized estimating equation marginal models were used in an intention-to-treat analysis to predict 7-day tobacco use abstinence. RESULTS: The average self-reported abstinence among participants varied considerably across facilities (0%-27%). Despite a significant increase in average cessation rate over time (0% at baseline to approximately 13% at 6 months; P < .0001), tobacco use did not differ by trial group at 14 days (OR, 0.96; 95% CI, 0.46-1.99; P = .90), 3 months (OR, 1.17; 95% CI, 0.69-1.99; P = .56), or 6 months (OR, 0.97; 95% CI, 0.65-1.43; P = .87). INTERPRETATION: The OaSiS trial participants showed a significant reduction in tobacco use over time, but no difference by trial arm was found. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03291587; URL: www. CLINICALTRIALS: gov.
引用
- Foley KL, Dressler EV, Weaver KE, et al. The Optimizing Lung Screening Trial (WF-20817CD): Multicenter Randomized Effectiveness Implementation Trial to Increase Tobacco Use Cessation for Individuals Undergoing Lung Screening. Chest. 2023. PMID: 36931460. doi:10.1016/j.chest.2023.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。